The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
LLM 2021 | Management of cold agglutinin disease
Sigbjorn Berentsen, MD, PhD, Haugesund Hospital, Haugesund, Norway, provides an overview of the current treatment landscape for cold agglutinin disease (CAD). Due to a previous lack of effective treatments, patients with mild cases of CAD were left untreated and with the arrival of novel therapies, a higher number of patients will benefit from treatment. The current recommended treatments include rituximab and bendamustine, with rituximab monotherapy being a suitable alternative in frail patients. Complement-targeted therapeutics are also a substitute to current regimens, but only treat symptoms relating to hemolytic anemia. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
